SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

The Boeing Co. is an aerospace company, which engages in the manufacture of commercial jetliners and defense, space, and security systems. It operates through the following segments: Commercial Airplanes (BCA), Defense, Space and Security (BDS), and Global Services (BGS). The Commercial Airplanes segment includes the development, production, and market of commercial jet aircraft and provides fleet support services, principally to the commercial airline industry worldwide. The Defense, Space and Security segment refers to the research, development, production and modification of manned and unmanned military aircraft and weapons systems for global strike, including fighter and combat rotorcraft aircraft and missile systems, global mobility, including tanker, rotorcraft and tilt-rotor aircraft, and airborne surveillance and reconnaissance, including command and control, battle management and airborne anti-submarine aircraft. The Global Services segment provides services to commercial and defense customers. The company was founded by William Edward Boeing on July 15, 1916, and is headquartered in Arlington, VA.

Boeing Co.

Boeing Co

Boeings quarterly loss was wider than expected, while managements cash-flow outlook and delayed 737 production ramp disappointed investors, prompting a sharp selloff. Traders are criticizing management and fearing further weakness, while others view the drop as overdone and point to Boeings backlog as a reason to keep buying.

Seagate Technology Holdings Plc operates as holding company that is engaged in the development, production, and distribution of data storage products and electronic data storage solutions. Its products include hard disk drives, solid state hybrid drives, solid state drives, peripheral component interconnect express cards, serial advanced technology attachment controllers, storage subsystems and computing solutions. The firm offers its products under the Backup Plus and Expansion product lines, and Maxtor and LaCie brands. The company was founded in 1978 and is headquartered in Fremont, CA.

Seagate Technology Holdings Plc

Seagates better-than-expected quarterly results and stronger outlook have drawn attention, but shares sold off despite the beat. Traders disagree over whether the reaction reflects elevated expectations and concerns about slowing margin growth or profit-taking, while many bullish voices view the decline as an overreaction to strong AI-related storage demand.

Enphase Energy, Inc. is a global energy technology company, which engages in the business of designing, developing, manufacturing, and selling home energy solutions that manage energy generation, energy storage, control, and communications on one intelligent platform. It operates through the following geographical segments: the United States, the Netherlands, and Others. The company was founded by Raghuveer R. Belur and Martin Fornage in March 2006 and is headquartered in Fremont, CA.

Enphase Energy Inc

Enphases disappointing third-quarter results and weaker fourth-quarter outlook are driving attention, with traders pointing to soft residential solar demand amid high interest rates and the expiring tax credit. Many are bearish on the near-term outlook, while some see a buying opportunity and cite AI data-center technology as a longer-term possibility that still needs to translate into sales.

SoFi Technologies, Inc. is a financial service platform, which engages in the provision of student loan refinancing options to the private student loan market. It operates through the following segments: Lending, Technology Platform, and Financial Services. The Lending segment offers personal loans, student loans, home loan products, and related servicing activities. The Technology Platform segment focuses on technology products and solutions revenue. The Financial Services segment includes the SoFi Money product, SoFi Invest product, SoFi Credit Card product, SoFi Relay personal finance management product, and other financial services. The company was founded in April 2011 and is headquartered in San Francisco, CA.

SoFi Technologies Inc

SoFis stronger-than-expected Q3 results and raised guidance, including an upbeat 2027 outlook, drove a sharp rally. Traders are celebrating growth and speculating that elevated short interest could amplify the move, while skeptics question the durability of lending-led growth and warn the rally could fade.

MARA Holdings, Inc. is a digital asset technology company, which engages in mining cryptocurrencies with a focus on the Bitcoin ecosystem. It also deals with owning and operating bitcoin mining facilities or data centers, selling proprietary software or technology to third parties operating in the Bitcoin ecosystem, offering advisory and consulting services to support Bitcoin mining ventures in domestic and international jurisdictions, and generating electricity from renewable energy resources or methane gas capture to power Bitcoin mining projects. The company was founded on February 23, 2010 and is headquartered in Hallandale Beach, FL.

MARA Holdings Inc.

Marathon Digital Holdings Inc

Traders are debating MARAs reported launch of its Vertebrai mining-as-a-service product, with many dismissing it as another concept without signed AI/data-center tenants or clear revenue progress. Bitcoin strength and oversold conditions are cited by some as support for a bounce, while others remain bearish over the prolonged selloff and managements execution.

BlackRock, Inc. engages in the provision of investment, advisory, and risk management solutions. Its products include single-asset and multi-asset portfolios. The company was founded by Laurence Douglas Fink and Robert Steven Kapito in 1988 and is headquartered in New York, NY.

Blackrock Inc.

BlackRocks quarterly earnings beat and strong client inflows, which lifted assets under management to a record, are driving attention and upbeat reactions. Some traders are parsing the gap between adjusted and GAAP results, including a noncash expense, rather than treating the headline beat as uniformly positive.

What is the project about? Pepe is a community based meme token surround the iconic meme Pepe the frog. Pepe aims to leverage the power of such an iconic meme to become the most memeable memecoin in existence.   What makes your project unique? Pepe is here to make memecoins great again. Ushering in a new paradigm for memecoins, Pepe represents the memecoin in it's purest simplicity. With zero taxes, liquidity locked forever, and contract immutable, Pepe is for the people, forever. Pepe is about culture, rallying together a community to have fun and enjoy memes, fueled purely by memetic power.   History of your project. Pepe was stealth launched on Friday, April 14th, 2023.   What’s next for your project? Pepe will focus on developing a tight-knit community around the token and building resources to enrich the communities knowledge and success in crypto through a token gated group, newsletter, and more tools.   What can your token be used for? Pepe can be used to speculate on the power of memes, and does not pretend to be anything more.

Pepe

A sharp PEPE rebound and renewed meme-coin momentum have fueled breakout talk, with some traders anticipating a move through resistance and renewed competition with SHIB. Others warn that rallies have faded quickly, question the volume behind the move, and point to PEPEs sensitivity to Bitcoin and broader crypto conditions.

Reddit, Inc. operates an entertainment, social networking, and news website where registered community members can submit content. The firm provides online news services where users can select and rank web content. It also offers a personalized filter on the day's story, using previous votes to determine what new things the user might like to read. The company was founded by Steven Ladd Huffman and Alexis Ohanian on June 23, 2005 and is headquartered in San Francisco, CA.

Reddit Inc. - Ordinary Shares - Class A

Reddit Inc

Reddits upcoming quarterly results are the main focus as shares face a sharp pullback, with traders watching user growthespecially U.S. daily active usersand advertising performance. Bears worry about slowing engagement, AI-related disruption and insider selling, while bulls argue that ad growth and Reddits data value support the business; speculation about AI licensing deals also features in the debate.

Robinhood Markets, Inc is a financial services platform, which engages in the provision of retail brokerage and offers trading in U.S. listed stocks and Exchange Traded Funds, related options, and cryptocurrency trading, as well as cash management, which includes debit cards services. The company was founded by Vladimir Tenev and Baiju Prafulkumar Bhatt in 2013 and is headquartered in Menlo Park, CA.

Robinhood Markets Inc - Ordinary Shares - Class A

Robinhood Markets Inc

Robinhoods quarterly results triggered a selloff after revenue came in below expectations, despite record revenue and growth in options and prediction markets. Traders are split between calling the drop an overreaction and buying the dip, and citing weaker crypto activity and pressure on earnings as reasons for caution.

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

BlackRocks filing disclosing a 7.9% stake is a central focus, with bulls treating the increased holding as institutional validation and skeptics noting it may reflect passive or index investing. Traders are also watching for the REGAL Phase 3 AML trials 80th-death trigger and eventual topline results, fueling short-squeeze speculation alongside debate over the trials prospects.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

UNIQURE N.V. QURE INVESTORS: Contact Kirby McInerney LLP About the Firms Securities Investigation Following 37.3% Share Drop

The law firm of Kirby McInerney LLP reminds investors of its investigation on behalf of uniQure N.V. (uniQure or the Company) (NASDAQ: QURE) investors concerning the Companys and/or members of its senior managements possible violation of the federal securities laws or other unlawful business...

uniQure Plunges on Additional Data From Huntington's Disease Study

QURE's Huntingtons gene therapy shows sustained functional benefits at 36 months, but mixed 48-month data add uncertainty. 

uniQure Investigation Notice: SueWallSt Notifies Investors of Pending Investigation Into uniQure (QURE)

uniQure Investigation Notice: SueWallSt Notifies Investors of Pending Investigation Into uniQure (QURE) uniQure Investigation Notice: SueWallSt Notifies Investors of Pending Investigation Into uniQure (QURE)PR NewswireNEW YORK, Sept. 29, 2026uniQure's four-year AMT-130 Huntington's disease benefit...

QURE Stock Clocks Worst Day In Over 10 Months: Four-Year Huntington’s Data Spooks Investors Despite Stronger Three-Year Filing Data  

Equity

uniQure said AMT-130 continued to slow Huntington’s disease in ongoing early- and mid-stage studies after four years. 


QURE Investors Have Opportunity to Join uniQure N.V. Fraud Investigation with SBS Law

Schall, Brown & Schwartz LLP (SBS), a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of uniQure N.V. (UniQure or the Company) (NASDAQ: QURE) for violations of the securities laws.INVESTIGATION DETAILS: The investigation focuses on...

QURE Stock Is On Track To Shed About Half Its Market Cap Despite Encouraging Huntington’s Disease Data – Here’s What Investors Need To Know

uniQure’s Ifezuntirgene slowed disease progression by 80% on a measure combining movement, thinking and daily function.


Stocktwits Pharma Pulse: Lilly, Novo Lead A Busy Week — Here Are The Stocks And Readouts To Watch 

Novo has 44 abstracts at EASD, including CagriSema analyses and Phase 2b Zenagamtide results.

Biotech Week Ahead: XLV Beats The Market — Here Are The Stocks, Readouts And Events To Watch Next 

Novo Nordisk (NVO) will hold its 2026 Capital Markets Day in London on Monday.

Spyre Therapeutics (SYRE) Down 16.6% Since Last Earnings Report: Can It Rebound?

Spyre Therapeutics (SYRE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

QURE Submits Application for Gene Therapy for Huntington's Disease

QURE seeks accelerated FDA approval for AMT-130, with Priority Review and a U.K. filing adding momentum to its regulatory push.

uniQure NV engages in the discovery, development, and commercialization of innovative gene therapies. Its discoveries intend to treat hemophilia, Huntington's disease, glybera, and cardiovascular problems. The company was founded by Sander J. van Deventer in 1998 and is headquartered in Amsterdam, Netherlands.

uniQure N.V.

Neutral Sentiment

<ul class="summary-bullets"><li>UniQure filed an application with the FDA seeking approval for the gene therapy earlier this month.&nbsp;</li><li>Stifel said the overall case for AMT-130 looks unchanged heading into regulatory review.</li><li>Wells Fargo argued the four-year composite reading is a secondary measure distorted by dropouts in the external control group and does not undo the three-year result that underpins the filing.&nbsp;</li></ul> Shares of uniQure (<a class="mention" data-mention="$QURE" data-symbol-id="QURE" href="https://stocktwits.com/symbol/QURE" target="_blank">QURE</a>) collapsed 37% on Tuesday after four-year results from its Huntington’s gene therapy study missed a key statistical test, even as the company said the treatment still slowed decline, and analysts largely kept bullish ratings.Shares clocked their worst day since Nov. 2025 and closed Monday at $24.51, down from Monday’s closing price of $39.11.<h2 class="st-heading-2">What The <a class="mention" data-mention="$QURE" data-symbol-id="QURE" href="https://stocktwits.com/symbol/QURE" target="_blank">QURE</a> Trial Showed</h2>uniQure said its one-time gene therapy, AMT-130, continued to slow Huntington’s disease in ongoing early- and mid-stage studies. Huntington’s is an inherited brain disorder with no approved treatment that changes how the disease unfolds.Patients received a single dose delivered into the brain. Their results were compared with similar patients from a large long-term disease database, not a conventional placebo group.The U.S. application filed earlier this month rests on three-year results. That snapshot covers 15 high-dose patients. On a broad score of thinking, movement and daily function, decline slowed by 80% following treatment. On a narrower score of everyday independence, it slowed decline by 67%. The company said both differences stood out in its analysis. The treatment was generally well tolerated. Most side effects were linked to the brain surgery used to deliver the therapy and later resolved.The first four-year look, limited to 12 high-dose patients, was weaker. Slowing on the broad score fell to 44% and missed statistical significance. Everyday independence still showed a 61% slowing. uniQure said the later comparison likely understated the benefit because many people in the control database dropped out, leaving a group that appeared to decline more slowly than typical Huntington’s patients.<h2 class="st-heading-2">Analysts Stay Constructive On <a class="mention" data-mention="$QURE" data-symbol-id="QURE" href="https://stocktwits.com/symbol/QURE" target="_blank">QURE</a></h2>Stifel kept a Buy rating. It said the expanded three-year results still look robust and that four-year data continue to support a drug effect, even if the composite score faded. Daily-function results held up, the firm said, and the overall case looks unchanged heading into regulatory review.H.C. Wainwright also kept a Buy rating and an $80 target. It called the broader three-year update encouraging but said the four-year composite result complicates the durability argument. Those later results were not part of the filed application. The next milestone, the firm said, is whether the FDA accepts the filing for review.RBC Capital’s Luca Issi called the package mixed. The four-year composite miss and the apparent fade from year three were not what the firm wanted to see, though daily-function benefit stayed consistent and comparisons across time points are imperfect. RBC still thinks approval is possible in a disease with a sharply elevated suicide risk and said the stock move looks overdone. It kept an Outperform rating.Wells Fargo reiterated an Overweight rating and a $75 target. It argued the four-year composite reading is a secondary measure distorted by dropouts in the external control group and does not undo the three-year result that underpins the filing. The firm called the selloff out of proportion and said the weakness may create a buying opportunity before the next regulatory update.<h2 class="st-heading-2">How Did <a class="mention" data-mention="$QURE" data-symbol-id="QURE" href="https://stocktwits.com/symbol/QURE" target="_blank">QURE</a> Retail Traders React?</h2>On Stocktwits, retail sentiment around <a class="mention" data-mention="$QURE" data-symbol-id="QURE" href="https://stocktwits.com/symbol/QURE" target="_blank">QURE</a> stock stayed within the extremely bullish territory over the past 24 hours, while message volume rose from high to extremely high levels.A Stocktwits user opined that despite the data announced on Tuesday, AMT-130 is “still the best hope for Huntington.”<stembedurl>https://stocktwits.com/Cap_00/message/665371669</stembedurl>Another dismissed the selloff on Tuesday as an overreaction.<stembedurl>https://stocktwits.com/Rixhard66774433/message/665358355</stembedurl><a href="https://stocktwits.com/symbol/QURE">QURE stock</a> has gained 2% year-to-date after Tuesday’s selloff.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/be-stock-recovers-after-monday-slide-on-analyst-support-peers-fcel-plug-edge-higher/cZMZQn3RBWL">BE Stock Recovers After Monday Slide On Analyst Support: Peers FCEL, PLUG Edge Higher</a>For updates and corrections, email newsroom[at]stocktwits[dot]com

In this photo illustration, the uniQure logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

uniQure said AMT-130 continued to slow Huntington’s disease in ongoing early- and mid-stage studies after four years. 

QURE Stock Clocks Worst Day In Over 10 Months: Four-Year Huntington’s Data Spooks Investors Despite Stronger Three-Year Filing Data

uniQure NV

Vanguard Extended Market ETF

SPDR S&P Biotech ETF

50bps hike

25bps hike

No change

Rate cut

The Federal Reserve announces its rate decision Wednesday, October 28 at 2:00 PM ET, followed by Chair Kevin Warsh’s press conference at 2:30 PM, after raising rates by a quarter point to 3.75%-4.00% in September, its first hike since 2023. What do you think the Fed decides on Wednesday? Vote and explain your reasoning in the comments.

Current Price	$24.28
Prev Close	$21.65
Open	$21.76
Dividend Yield	0.00%
50-Day Moving Average	$35.95
Beta	1.35
Avg. Volume	3.07M
PE Ratio	-6.00

52-Week High	$70.88
52-Week Low	$8.73
Market Capitalization	$1.68B
EPS (Annual)	-$3.46
Price to Book	5.20
Revenue Per Employee	$72,841.63

Feed

News

Sentiment

Earnings

Fundamentals

Info

QURE Fundamentals